PROK
PROKIDNEY CORP.
NASDAQ · Healthcare · Biotechnology · US
$1.40
+4.89%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.35
From 52W high−57.73%
Volume911853.00
Market cap$291.45M
P/E (TTM)—
P/S (TTM)356.3x
Div yield—
Key dataOct 19, 2026
Open
$1.35
From 52W high
−57.73%
Volume
911853.00
Market cap
$291.45M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.6x
P/E (TTM)
—
RSI (14)
37.1
MomentumView details →
1D Return
+4.89%
YTD Return
−37.95%
SummaryUpdated Jun 1, 2026
ProKidney Corp. (NASDAQ:PROK) is a clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. The company went public in June 2021 and focuses on developing innovative cellular therapy treatments for kidney diseases. ProKidney is currently advancing its lead product candidate, Renal Autologous Cell Therapy (REACT), through Phase III clinical trials for diabetic kidney disease, representing a potentially groundbreaking approach to treating chronic kidney conditions that affect millions of patients worldwide.
Similar companies
Latest newsMore news →
ProKidney Corp. announced that eight abstracts, including one oral presentation, were selected for presentation at the American Society of Nephrology's Kidney Week 2026, to be held October 21-25, 2026, in Denver, Colorado.17d agoProKidney Corp. reported a second-quarter loss of $0.15 per share, missing the Zacks Consensus Estimate of a $0.13 loss and matching the year-ago loss of $0.13 per share.70d ago